Business Context and Reporting Period
OneWater Marine Inc. filed this Form 8-K on August 9, 2022, reporting the closing of two acquisitions and the entry into an amended and restated credit facility. The filing does not report quarterly or annual operating results for a comparable period.
Key Financial Metrics and Financing
- Credit facility: $65.0 million revolving facility and $445.0 million initial term loan facility, for total initial commitments of $510.0 million.
- Capacity expansion: Subject to conditions, commitments may increase by up to $125.0 million, including up to $50.0 million for the revolver.
- Revolver balance: No borrowings were outstanding under the revolving facility immediately after closing.
- Maturity: The revolving facility and remaining term loan balance mature on August 9, 2027. Term loan installments begin December 31, 2022.
- Interest: Borrowings bear interest at either a base rate plus a margin of up to 1.75% or Term SOFR plus a margin ranging from 1.75% to 2.75%; margins depend on consolidated leverage.
- Uses of proceeds: Term loan proceeds and cash on hand were used for capital expenditures, permitted acquisitions, working capital and general corporate purposes.
- Acquisition consideration: Ocean Bio-Chem was acquired for approximately $124.4 million, based on approximately $13.08 per share. Star Brite Europe was acquired for $7.0 million, subject to adjustments. The company also acquired certain real property, but the filing does not provide a purchase price for that property.
Material Changes Versus the Prior Comparable Period
- The prior credit agreement, originally dated July 22, 2020 and subsequently amended, was amended and restated on August 9, 2022.
- OneWater completed its previously announced acquisition of Ocean Bio-Chem, Inc. and its acquisition of Star Brite Europe, Inc., materially expanding its operations and increasing financing obligations.
- The filing does not provide comparative revenue, profit, cash flow, margin, liquidity or balance-sheet figures.
Guidance, Outlook, Risks and Unusual Items
- The filing provides no formal financial guidance or quantified outlook.
- The credit facility requires compliance with a minimum fixed-charge coverage ratio and maximum consolidated leverage ratio, along with customary non-financial covenants restricting additional debt, asset transfers, investments, restricted payments and affiliate transactions.
- Events of default, borrowing conditions, representations, indemnification and expense-reimbursement provisions apply under the credit agreement.
- Management represented that the company was in compliance with all credit facility covenants as of the closing date.
- The acquisitions were funded with cash on hand and borrowings under the amended credit facility, increasing leverage and integration exposure.
- Financial statements and pro forma financial information, if required, were to be filed by amendment; the filing does not include those results.
Important Facts for Investors to Verify
- Review subsequent filings for the acquisition-date accounting, purchase-price allocation, goodwill, identifiable intangibles and pro forma operating results.
- Verify the amount of term debt actually drawn, cash used and remaining liquidity after closing.
- Monitor required term loan amortization beginning December 31, 2022, covenant compliance and leverage-based interest margins.
- Assess Ocean Bio-Chem and Star Brite Europe revenue, profitability, integration progress and any acquisition-related synergies or costs.
- Confirm the purchase price and terms of the acquired real property, which are not clearly quantified in this filing.